Search This Blog

Monday, May 6, 2024

BioCryst Strong Q1 2024 Results

 

  • Q1 2024 Revenue: Reported at $92.8 million, a 34.9% increase year-over-year, surpassing the estimated $85.6 million.

  • Net Loss: Recorded at $35.4 million for Q1 2024, an improvement from a net loss of $53.3 million in Q1 2023, and better than the estimated net loss of $43.01 million.

  • Earnings Per Share (EPS): Reported at -$0.17, better than the estimated -$0.21.

  • ORLADEYO Net Revenue: Grew by 30% year-over-year to $88.9 million, driving the majority of the quarter's revenue.

  • Research and Development (R&D) Expenses: Decreased by 3.9% year-over-year to $46.5 million, reflecting strategic cuts and reallocation.

  • Selling, General and Administrative (SG&A) Expenses: Increased by 24% year-over-year to $59.4 million, due to expansion efforts.

  • 2024 Financial Outlook: Adjusted full-year ORLADEYO revenue guidance to $390-$400 million, indicating strong performance and market confidence.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.